SRF231 CD47 Antibody
CD47 is overexpressed by multiple tumor types and functions as an important immune escape mechanism. CD47-overexpressing tumor cells communicate a “don’t eat me” signal (macrophage checkpoint), which prevents them from being engulfed and eliminated by macrophages. Because of the number of cancers that express CD47, it is a target with broad therapeutic potential.
SRF231 blocks the CD47 signal and makes tumor cells vulnerable to macrophage attack. Preclinical studies of SRF231 have shown that it binds with high affinity to CD47, stimulates phagocytosis of cancer cells in vitro, and has potent in vivo anti-tumor activity, both as monotherapy and in combination settings. SRF231 does not induce detectable hemagglutination or phagocytosis of red blood cells in vitro, a potentially important safety advantage.
SRF231 is the lead compound in the Company’s growing pipeline and the first option target in the strategic collaboration with Novartis under which Surface has the option to retain 100% of the US development and commercial rights. SRF231 is in late preclinical development and is expected to enter clinical trials in 2017.